|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007137,
umls-concept:C0014852,
umls-concept:C0026882,
umls-concept:C0032854,
umls-concept:C0033325,
umls-concept:C0078058,
umls-concept:C0079419,
umls-concept:C0205179,
umls-concept:C0332281,
umls-concept:C1171892,
umls-concept:C1306673,
umls-concept:C1561558
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
1998-6-29
|
|
pubmed:abstractText |
Vascular endothelial growth factor (VEGF) affects malignant tumours by promoting angiogenesis. The tumour-suppressor gene p53 has been thought to regulate VEGF. We investigated the effect of VEGF on oesophageal carcinoma and the connection between VEGF and p53. One hundred and nine resected oesophageal squamous cell carcinomas were examined. VEGF expression was analysed by immunohistochemical staining. Sixty-five tumours (59.6%, 65 out of 109) were classified as VEGF positive. A significant correlation was found between the VEGF expression and both the depth of invasion (P = 0.0001) and lymph node metastasis (P < 0.0001). With regard to p53, we compared the expression of VEGF with the mutation of p53, examined using polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) and direct sequencing in tumour samples obtained from 36 patients who we have reported previously. The VEGF expression was significantly correlated to p53 mutation (P = 0.0291). To evaluate the angiogenesis, microvascular density (MVD) was counted, and endothelial cells were stained immunohistochemically using anti-CD34 monoclonal antibody against 29 cases with invasion limited to the submucosal layer. The average MVD had a tendency to correlate to VEGF expression (P = 0.1626). The prognoses of patients with VEGF-positive primary tumours were significantly worse than for those with VEGF-negative primary tumours (P = 0.0077). We have assumed that VEGF contributes to aggressive characteristics in oesophageal carcinomas and that VEGF expression might be affected by p53 status.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/9635853-1279431,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9635853-1372863,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9635853-1377162,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9635853-1694687,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9635853-1711045,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9635853-1728357,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9635853-1755866,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9635853-2020552,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9635853-2735925,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9635853-7507853,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9635853-7525492,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9635853-7730348,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9635853-8094033,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9635853-8108142,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9635853-8466753,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9635853-8521408,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9635853-8575860,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9635853-8653715,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9635853-8782456,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9635853-9010094,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9635853-9816044
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
77
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1704-9
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:9635853-Carcinoma, Squamous Cell,
pubmed-meshheading:9635853-Endothelial Growth Factors,
pubmed-meshheading:9635853-Esophageal Neoplasms,
pubmed-meshheading:9635853-Female,
pubmed-meshheading:9635853-Genes, p53,
pubmed-meshheading:9635853-Humans,
pubmed-meshheading:9635853-Immunohistochemistry,
pubmed-meshheading:9635853-Lymphatic Metastasis,
pubmed-meshheading:9635853-Lymphokines,
pubmed-meshheading:9635853-Male,
pubmed-meshheading:9635853-Mutation,
pubmed-meshheading:9635853-Neoplasm Metastasis,
pubmed-meshheading:9635853-Prognosis,
pubmed-meshheading:9635853-Tumor Cells, Cultured,
pubmed-meshheading:9635853-Vascular Endothelial Growth Factor A,
pubmed-meshheading:9635853-Vascular Endothelial Growth Factors
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis.
|
|
pubmed:affiliation |
Department of Surgery & Surgical Basic Science, Graduate School of Medicine, Kyoto University, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
